GO
Loading...

Medicine

More

  • Animalistic Behavior Against Novartis Tuesday, 4 Aug 2009 | 2:38 PM ET
    Dash

    Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.

  • Merck's First Or Only Shot? Monday, 3 Aug 2009 | 11:57 AM ET

    This Friday Merck and Schering-Plough shareholders are set to vote on the mega-merger. When companies co-mingle it's standard operating procedure for heads to roll. So-called "cost-saving synergies" are a big reason why deals like this get done. But this out-of-the-blue departure seems to have nothing to do with that.

  • Lack of Study Volunteers May Hobble Cancer Fight Monday, 3 Aug 2009 | 10:58 AM ET
    Cancer Treatment

    The biggest barrier to improved cancer treatments is that almost no adult cancer patients — just 3 percent — participate in studies of cancer treatments, mostly new drugs or drug regimens.

  • The Summer of Biotech Friday, 31 Jul 2009 | 4:21 PM ET
    Pharma Stocks

    Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.

  • Your Health Policy Has Been Canceled Tuesday, 28 Jul 2009 | 11:39 AM ET
    Healthcare coverage and the hastle of forms

    Government-run insurance could not be worse than what small businesses already face.

  • A Washington Drug Bust Monday, 27 Jul 2009 | 11:04 AM ET

    The drug companies help pay my salary. Not directly, of course (although I bet there are conspiracy theorists out there who are probably convinced they do), but they undoubtedly contribute a sizeable amount of advertising dollars to the company I work for.

  • Lilly's Side-Effect Slip-Up Thursday, 23 Jul 2009 | 3:33 PM ET

    I'm betting somebody's blood pressure at Eli Lilly headquarters in Indianapolis today went through the roof.

  • Biopharma Gets Its Groove On Thursday, 23 Jul 2009 | 1:42 PM ET

    What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.

  • Costly Drugs Known as Biologics Prompt Exclusivity Debate Wednesday, 22 Jul 2009 | 11:11 AM ET

    A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?

  • Merck Hangs Out The Shingle Tuesday, 21 Jul 2009 | 11:43 AM ET
    Shingles image from Zostavax.com

    Recently, Merck came out with the first vaccine for shingles called Zostavax. But it had manufacturing and supply issues that hurt the launch. In its earnings press release today, Merck says as of last month it has "resumed normal shipping schedules for Zostavax."

  • Teva, Propofol And Michael Jackson Friday, 17 Jul 2009 | 4:08 PM ET
    Michael Jackson

    The Food and Drug Administration today announced that Teva Pharmaceutical Industries is voluntarily recalling two lots of the anesthetic Propofol because there are higher levels of potentially fatal endotoxins...Propofol is the same drug that was reportedly found in Michael Jackson’s house.

  • A Tysabri Turnaround Or A Head Fake? Thursday, 16 Jul 2009 | 4:00 PM ET
    Carl Icahn

    Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.

  • My ICAD Infraction: One Year Later Wednesday, 15 Jul 2009 | 3:28 PM ET

    Man, time flies. I can't believe almost a year has passed since the incident at ICAD. That's the big Alzheimer's Disease scientific research conference that was held in Chicago in late July last year. This year, it's in Vienna and it's going on right now.

  • All In The Family Tuesday, 14 Jul 2009 | 11:34 AM ET
    Mike and his sister.

    For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.

  • Is Lilly's Effient Sufficient? Monday, 13 Jul 2009 | 11:28 AM ET

    I was wrong. I'd blogged a few times that I thought the FDA might have a problem with "Effient," Eli Lilly's proposed name for its bloodthinner, because it was too close to efficient and all the connotations that would have.

  • It's a Numbers Game for Merck & Glaxo Tuesday, 7 Jul 2009 | 12:49 PM ET

    Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.

  • Hey, What's Up Doc? Monday, 6 Jul 2009 | 11:55 AM ET
    Bugs Bunny

    Could a carrot-chomping Bugs Bunny become a drug pitchman? Well, maybe, if the small Israeli company Protalix BioTherapeutics could pay Warner Brothers enough money for Bugs' services.

  • FDA: Thinking Outside The Black Box Wednesday, 1 Jul 2009 | 3:25 PM ET
    Zyban Prescribing Information

    Today the Food and Drug Administration announced that Pfizer's Chantix and GlaxoSmithKline's Zyban will carry new warnings about mental side effects. Not just any old warnings, but so-called "Black Box" warnings. Or, at least, that's what we in the news media used to call them. Until the FDA called us out today.

  • Looking For The Lantus Leak Monday, 29 Jun 2009 | 11:23 AM ET
    Sanofi Aventis

    Shares of Sanofi-Aventis are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday.

  • A Sanofi Safety Scare? Friday, 26 Jun 2009 | 1:18 PM ET
    Sanofi Aventis

    Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could go public soon. Their research suggests the data is related to a suspected or "theoretical" higher cancer risk associated with SNY's Lantus.